Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series

1

Tildrakizumab 200 mg showed high effectiveness in patients with moderate-to-severe psoriasis and multiple comorbidities.
2

Most patients achieved PASI90 or PASI100 responses within 4–12 weeks, with complete clearance in four out of six cases.
3

Treatment effectiveness was maintained over approximately 24 months, demonstrating a favorable safety profile.
4

The study highlights the challenges of managing psoriasis in patients with high disease burden and difficult-to-treat areas.
5

Real-world evidence supports the use of tildrakizumab for patients with prior therapeutic failures and complex clinical profiles.

Frontiers In Medicine

by Giulia Odorici, Cinzia Buligan, Carolina Fantini, Lucia Mantovani, Giulia Rech, Lidia Sacchelli
July 14, 2026

1